Guyasuta Investment Advisors Inc. decreased its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 168,031 shares of the medical instruments supplier's stock after selling 8,702 shares during the period. Becton, Dickinson and Company accounts for 1.9% of Guyasuta Investment Advisors Inc.'s investment portfolio, making the stock its 15th largest holding. Guyasuta Investment Advisors Inc. owned about 0.06% of Becton, Dickinson and Company worth $32,610,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Activest Wealth Management boosted its holdings in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth $25,000. SOA Wealth Advisors LLC. boosted its stake in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 95 shares during the period. Accredited Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 70 shares during the period. Finally, Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 139 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.
Becton, Dickinson and Company Stock Down 0.1%
Shares of Becton, Dickinson and Company stock opened at $154.07 on Monday. The company has a market cap of $43.87 billion, a P/E ratio of 25.13, a PEG ratio of 10.97 and a beta of 0.29. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The firm has a fifty day moving average of $170.95 and a two-hundred day moving average of $185.36.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts' consensus estimates of $2.81 by $0.10. The company had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company announced that its Board of Directors has approved a stock buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its shares are undervalued.
Becton, Dickinson and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were given a dividend of $1.05 per share. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company's dividend payout ratio is presently 68.52%.
Insiders Place Their Bets
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director owned 36,763 shares of the company's stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 2,713 shares of company stock valued at $536,881. 0.40% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on BDX. TD Cowen increased their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a "hold" rating in a research note on Wednesday, February 11th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research note on Friday. They set a "neutral" rating and a $167.00 price target for the company. Bank of America increased their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a "neutral" rating in a research note on Monday, January 5th. Royal Bank Of Canada set a $172.00 price target on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Finally, Barclays began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an "overweight" rating and a $202.00 price target for the company. Six research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average target price of $189.69.
Check Out Our Latest Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
